Filing Details

Accession Number:
0000947871-21-000797
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2021-07-23 17:30:18
Reporting Period:
2021-07-16
Accepted Time:
2021-07-23 17:30:18
Original Submission Date:
2021-07-16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Imara Inc. IMRA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022-4629
Yes No Yes No
1760648 Orbimed Capital Gp Vii Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-16 1,666,666 $6.00 4,199,068 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Footnotes
  1. These shares of the Issuer's common stock ("Shares") were purchased in the Company's underwritten public offering. The previously reported acquisition of these Shares was inadvertently attributed to OrbiMed Partners Master Fund Limited.
  2. The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
  3. This report on Form 4 is filed by OrbiMed Advisors and GP VII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or David Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.